GAITHERSBURG, Md., Aug. 4, 2022 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines…
Browsing: Novavax
Nuvaxovid™ is the first protein-based COVID-19 vaccine approved for use in adolescents in Japan GAITHERSBURG, Md., July 26, 2022 /PRNewswire/…
GAITHERSBURG, Md., July 19, 2022 /PRNewswire/ — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation…
Agreement will provide the first protein-based vaccine option in the U.S., pending FDA Emergency Use Authorization and CDC recommendation GAITHERSBURG,…
Nuvaxovid™ COVID-19 vaccine is the first protein-based option for adolescents aged 12 through 17 in Europe GAITHERSBURG, Md., July 5,…
In Australia, Nuvaxovid™ is the first protein-based COVID-19 vaccine registered for use as a booster regardless of previous vaccine history…
News ReleaseMonday, June 14, 2021 Results from a Phase 3 clinical trial enrolling 29,960 adult volunteers in the United States…
Después de importantes retrasos en su producción y aprobación, Novavax, la primera vacuna a base de proteínas contra el Covid-19…